In a report released on September 28, Ann Hynes from Mizuho Securities reiterated a Buy rating on Quest Diagnostics (DGX – Research Report), with a price target of $160.00. The company’s shares closed yesterday at $124.62.
Hynes covers the Healthcare sector, focusing on stocks such as HCA Healthcare, Tenet Healthcare, and Cardinal Health. According to TipRanks, Hynes has an average return of 6.0% and a 53.80% success rate on recommended stocks.
Currently, the analyst consensus on Quest Diagnostics is a Moderate Buy with an average price target of $147.11.
See the top stocks recommended by analysts >>
The company has a one-year high of $171.72 and a one-year low of $120.40. Currently, Quest Diagnostics has an average volume of 851.5K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Quest Diagnostics, Inc. engages in the provision fo diagnostic testing, information and services. It operates through the Diagnostic Information Services (DIS) and All Other segments. The DIS segment offers diagnostic information services to patients, clinicians, hospitals, health plans, and employers. The All Other segment consists of risk assessment services, healthcare information technology, diagnostic products, and clinical trials testing businesses. The company was founded in 1967 and is headquartered in Secaucus, NJ.
Read More on DGX:
